Special Focus Session

SF 15 - Strategy for primary diagnosis of prostate cancer

March 4, 14:00 - 15:30 CET

SF 15-1
5 min
Chairperson's introduction
SF 15-2
18 min
Unmet clinical needs in prostate cancer
1. To understand how to select men for early diagnosis strategies for prostate cancer.
2. To learn about accurate prebiopsy imaging of suspect lesions in the prostate.
3. To become familiar with the role of PSMApet in early prostate cancer diagnosis.
4. To become familiar with the role of fusion biopsies in prostate cancer detection.
SF 15-3
18 min
The new role of ultrasound
1. To understand the limited intrinsic value of conventional B-mode and colour Doppler imaging for the diagnosis of prostate cancer.
2. To learn how to improve the diagnostic capabilities of conventional ultrasound using shear-wave elastography and contrast-enhanced US.
3. To be able to combine MRI information with US information using several types of fusion techniques.
4. To learn how to design a biopsy protocol based on the identification of multiple targets using combined MRI and US data.
5. To be able to extend the use of fusion imaging for both transrectal and transperineal biopsies.
SF 15-4
18 min
Current and future role of multiparametric MRI (mpMRI)
1. To learn how to perform, interpret, and communicate multiparametric MRI of the prostate in accordance with international guidelines.
2. To understand the role of mpMRI for image-guided biopsy and treatment decision making.
3. To become familiar with the current developments of artificial intelligence for improvement of mpMRI within the clinical context.
SF 15-5
18 min
PSMA applicability and potential developments in primary diagnosis and characterisation of prostate cancer
1. To become familiar with the current role of PSMA PET for staging prostate cancer.
2. To understand the impact of tumour heterogeneity for cancer detection and the potential added value of PSMA for disease detection.
3. To learn about potential future targets for prostate cancer PET.
SF 15-6
13 min
Panel discussion: From turf battles by evidence to joint patient care